Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Shanghai BDgene Technology

Main focus: mRNA-mediated delivery of gene-editing systems

Company stage: Clinical

Diseases: wet age-related macular degeneration (wAMD), glucoma, multiple other undisclosed diseases

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Shanghai, China

Website: https://bdgenetherapeutics.com/

Pipeline: https://bdgenetherapeutics.com/en/BD111.html

Shanghai BDgene Technology uses it proprietary technology, BDmRNA, to deliver gene-editing systems for the treatment of genetic diseases. The technology is thought to reduce the probability of off-target gene editing, and improve the safety of gene-editing medicines. Currently, the company is developing multiple pre-clinical programmes.

Shanghai BDgene Technology Co., Ltd.

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Shanghai BDgene Technology

Search CRISPR Medicine